Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Research Site
mi
from
Parkville,
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Research Site
mi
from
Parkville,
Click here to add this to my saved trials
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Zinc Supplements in Lowering Cadmium Levels in Smokers
Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers?
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study
Status: Enrolling
Updated:  1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Gefitinib, Docetaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
ZD-1839 (Iressa®) With Concurrent Docetaxel and Conformal Three Dimensional Thoracic Radiation Followed by Consolidative Docetaxel and ZD-1839 for Patients With Stage III Non Small Cell Lung Cancer: A Phase I Study
Status: Enrolling
Updated: 1/18/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated:  1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer
Evaluation of a Yoga-Based Cancer Rehabilitation Program
Status: Enrolling
Updated: 1/23/2017
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/26/2017
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Phase I/II Study of Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/26/2017
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated:  1/31/2017
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma
Status: Enrolling
Updated: 1/31/2017
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gene Polymorphisms and Symptoms in Lung Cancer Patients
Gene Polymorphisms and Symptoms in Lung Cancer Patients
Status: Enrolling
Updated:  2/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Gene Polymorphisms and Symptoms in Lung Cancer Patients
Gene Polymorphisms and Symptoms in Lung Cancer Patients
Status: Enrolling
Updated: 2/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/18/2017
Robert Wood Johnson University Hospital at Hamilton
mi
from
Hamilton, NJ
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/18/2017
Robert Wood Johnson University Hospital at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated:  2/18/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)
Status: Enrolling
Updated: 2/18/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Park Ridge, IL
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
St. Louis, MO
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Murray, UT
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Murray, UT
Click here to add this to my saved trials
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Dijon,
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Analysis of the Expression of a Specific Set of Genes and Tumor Antigens in Patients With Non-small Cell Lung Cancer or Melanoma
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Dijon,
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Newark, DE
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Newark, DE
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Springfield, IL
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Springfield, IL
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Rochester, MN
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Manchester, NJ
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Manchester, NJ
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
New York, NY
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Philadelphia, PA
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Everett, WA
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Everett, WA
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Seattle, WA
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/2/2017
GSK Investigational Site
mi
from
Tallinn,
A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor
GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/2/2017
GSK Investigational Site
mi
from
Tallinn,
Click here to add this to my saved trials
PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening
Promoting Informed Decisions About Lung Cancer Screening: Randomized Trial
Status: Enrolling
Updated:  3/7/2017
Information and Quality Healthcare (IQH)
mi
from
Ridgeland, MS
PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening
Promoting Informed Decisions About Lung Cancer Screening: Randomized Trial
Status: Enrolling
Updated: 3/7/2017
Information and Quality Healthcare (IQH)
mi
from
Ridgeland, MS
Click here to add this to my saved trials
Metabolism of NNK Among African Americans
Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking: Project 5: Metabolism of NNK Among African Americans
Status: Enrolling
Updated:  3/13/2017
Tobacco Research Programs University of Minnesota
mi
from
Minneapolis, MN
Metabolism of NNK Among African Americans
Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking: Project 5: Metabolism of NNK Among African Americans
Status: Enrolling
Updated: 3/13/2017
Tobacco Research Programs University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
New Haven, CT
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  3/15/2017
Merck Sharp & Dohme Co. Ltd.
mi
from
Hod Hasharon,
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 3/15/2017
Merck Sharp & Dohme Co. Ltd.
mi
from
Hod Hasharon,
Click here to add this to my saved trials
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated:  3/21/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated: 3/21/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated:  3/21/2017
Gemelli Hospital Roma / Universita Cattolica del Sacre Cuore Rome
mi
from
Rome,
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated: 3/21/2017
Gemelli Hospital Roma / Universita Cattolica del Sacre Cuore Rome
mi
from
Rome,
Click here to add this to my saved trials
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/4/2017
Syracuse VA Medical Center
mi
from
Syracuse, NY
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/4/2017
Syracuse VA Medical Center
mi
from
Syracuse, NY
Click here to add this to my saved trials
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/4/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A Phase II Study of Fraility Index and Geriatric Assessment as Predictors of Toxicity to Front-Line Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/4/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated:  4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors
Status: Enrolling
Updated: 4/4/2017
Wexner Medical Center at The Ohio State University Department of Psychiatry
mi
from
Columbus, OH
Click here to add this to my saved trials
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Status: Enrolling
Updated:  4/5/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Status: Enrolling
Updated: 4/5/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Colorado Cancer Center, Anschutz Medical Campus
mi
from
Denver, CO
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Colorado Cancer Center, Anschutz Medical Campus
mi
from
Denver, CO
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Pittsburgh Medical Center Cancer Center
mi
from
Pittsburgh, PA
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Pittsburgh Medical Center Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Washington University School of Medicine
mi
from
St. Louis, MO
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/12/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/12/2017
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated:  4/18/2017
Ironwood Cancer and Research Center
mi
from
Chandler, AZ
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated: 4/18/2017
Ironwood Cancer and Research Center
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated:  4/18/2017
South Bay Hematology Oncology
mi
from
Campbell, CA
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated: 4/18/2017
South Bay Hematology Oncology
mi
from
Campbell, CA
Click here to add this to my saved trials
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated:  4/18/2017
Medical Oncology Care Associates
mi
from
Orange, CA
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated: 4/18/2017
Medical Oncology Care Associates
mi
from
Orange, CA
Click here to add this to my saved trials
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated:  4/18/2017
American Institute of Research
mi
from
Whittier, CA
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated: 4/18/2017
American Institute of Research
mi
from
Whittier, CA
Click here to add this to my saved trials
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated:  4/18/2017
Florida Cancer Specialists
mi
from
Fort Myers, FL
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated: 4/18/2017
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated:  4/18/2017
Georgia Cancer Specialists
mi
from
Atlanta, GA
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated: 4/18/2017
Georgia Cancer Specialists
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated:  4/18/2017
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Status: Enrolling
Updated: 4/18/2017
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials